OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer

被引：0
|
作者：
Nicum, S. [1 ]
Strauss, V. Y. [2 ]
McGregor, N. [3 ]
McNeish, I. [4 ]
Roux, R. [1 ]
Hall, M. [5 ]
Michael, A. [6 ]
Roberts, C. [2 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Dept Oncol, Oxford, England
[2] Univ Oxford, Ctr Stat Med, Oxford, England
[3] Univ Oxford, Dept Oncol, Oncol Clin Trials Off, Oxford, England
[4] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland
[5] East & North Hertfordshire NHS Trust, Mt Vernon Canc Ctr, Stevenage, Middx, England
[6] Univ Surrey, Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
989TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.
    Zettler, Christie
    De Silva, Dilanka
    Blinder, Victoria Susana
    Robson, Mark E.
    Elkin, Elena B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
    Penson, Richard T.
    Valencia, Ricardo Villalobos
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A.
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos Hernandez
    Mora, Paulo Alexandre Ribeiro
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
    Lorusso, D.
    Scambia, G.
    Pignata, S.
    Sorio, R.
    Amadio, G.
    Lepori, S.
    Mosconi, A.
    Pisano, C.
    Mangili, G.
    Maltese, G.
    Sabbatini, R.
    Artioli, G.
    Gamucci, T.
    Di Napoli, M.
    Capoluongo, E.
    Ludovini, V.
    Raspagliesi, F.
    Ferrandina, G.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 487 - 493
  • [44] PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, J. E.
    Vallier, A-L
    Qian, W.
    Grybowicz, L.
    Thomas, S.
    Mahmud, S.
    Harvey, C.
    McAdam, K.
    Hughes-Davies, L.
    Roylance, R.
    Copson, E.
    Brown, J.
    Provenzano, E.
    Tischkowitzand, M.
    Earl, H. M.
    CANCER RESEARCH, 2017, 77
  • [45] PARTNER: randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, Jean E.
    Pinilla, Karren
    Vallier, Anne-Laure
    Grybowicz, Louise
    Qian, Wendi
    Thomas, Stanly
    Weiss, Melanie
    Harvey, Caron
    Kateb, Angels
    Machin, Andrea
    Demiris, Nikolaos
    Wulff, Jerome
    McAdam, Karen
    Hughes-Davies, Luke
    Roberts, Anne
    Roylance, Rebecca
    Copson, Ellen
    Armstrong, Anne
    Levitt, Nicky
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 585 - 586
  • [46] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Drewett, Lynsey M.
    Pinilla, Karen A.
    Grybowicz, Louise
    Wulff, Jerome
    Dayimu, Alimu
    Demiris, Nikolaos
    Martin, Jessica
    De Pontes, Camila Maida
    Johnson, Nicola
    Harvey, Caron
    Demir, Erdem
    Green, Kimberley St John
    Jones, James
    Young, Gemma
    Vallier, Anne-Laure
    Qian, Wendi
    Machin, Andrea
    McAdam, Karen
    Roylance, Rebecca
    Copson, Ellen R.
    Armstrong, Anne
    Levitt, Nicola
    Provenzano, Elena
    Tischkowitz, Marc
    McMurtry, Emma
    Earl, Helena
    Abraham, Jean E.
    CANCER RESEARCH, 2022, 82 (04)
  • [47] PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
    Abraham, J.
    Vallier, A-L
    Qian, W.
    Machin, A.
    Grybowicz, L.
    Thomas, S.
    Weiss, M.
    Harvey, C.
    McAdam, K.
    Hughes-Davies, L.
    Roberts, A.
    Roylance, R.
    Copson, E.
    Pinilla, K.
    Armstrong, A.
    Provenzano, E.
    Tischkowitz, M.
    McMurty, E.
    Earl, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.
    Drewett, Lynsey
    Lucey, Rebecca
    Pinilla, Karen Andrea
    Grybowicz, Louise
    Wulff, Jerome
    Dayimu, Alimu
    Demiris, Nikos
    Vallier, Anne-Laure
    Qian, Wendi
    Machin, Andrea
    McAdam, Karen
    Roylance, Rebecca
    Copson, Ellen
    Armstrong, Anne C.
    Levitt, Nicola
    Provenzano, Elena
    Tischkowitz, Marc D.
    McMurtry, Emma
    Earl, Helena Margaret
    Abraham, Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
    Senkus, Elzbieta
    Delaloge, Suzette
    Domchek, Susan M.
    Conte, Pierfranco
    Im, Seock-Ah
    Xu, Binghe
    Armstrong, Anne
    Masuda, Norikazu
    Fielding, Anitra
    Robson, Mark
    Tung, Nadine
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 803 - 814
  • [50] Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S.
    Postel-Vinay, S.
    Im, S-A.
    Park, Y. H.
    Delord, J-P.
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Wang, D.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Lai, Z.
    Gresty, C.
    Opincar, L. M.
    Herbolsheimer, P.
    Kaufman, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 477 - 477
12345